Literature DB >> 25619443

Sinus bradycardia during hypothermia in comatose survivors of out-of-hospital cardiac arrest - a new early marker of favorable outcome?

Jakob Hartvig Thomsen1, Christian Hassager2, John Bro-Jeppesen2, Helle Søholm2, Niklas Nielsen3, Michael Wanscher4, Lars Køber2, Steen Pehrson2, Jesper Kjaergaard2.   

Abstract

BACKGROUND: Bradycardia is a common finding in patients undergoing therapeutic hypothermia (TH) following out-of-hospital cardiac arrest (OHCA), presumably as a normal physiological response to low body temperature. We hypothesized that a normal physiological response with sinus bradycardia (SB) indicates less neurological damage and therefore would be associated with lower mortality.
METHODS: We studied 234 consecutive comatose survivors of OHCA with presumed cardiac etiology and shockable primary rhythm, who underwent a full 24-h TH-protocol (33°C) at a tertiary heart center (years: 2004-2010). Primary endpoint was 180-day mortality; secondary endpoint was favorable neurological outcome (180-day cerebral performance category: 1-2).
RESULTS: SB, defined as sinus rhythm <50 beats per minute during TH, was present in 115 (49%) patients. Baseline characteristics including sex, witnessed arrest, bystander cardiopulmonary resuscitation and time to return of spontaneous circulation were not different between SB- and no-SB patients. However, SB-patients were younger, 57±14 vs. 63±14 years, p<0.001 and less frequently had known heart failure (7% vs. 20%, p<0.01). Patients experiencing SB during the hypothermia phase of TH had a 17% 180-day mortality rate compared to 38% in no-SB patients (p<0.001), corresponding to a 180-day hazard ratio (HRadjusted=0.45 (0.23-0.88, p=0.02)) in the multivariable analysis. Similarly, SB during hypothermia was directly associated with lower odds of unfavorable neurological outcome (ORunadjusted=0.42 (0.23-0.75, p<0.01).
CONCLUSION: Sinus bradycardia during therapeutic hypothermia is independently associated with a lower 180-day mortality rate and may thus be a novel, early marker of favorable outcome in comatose survivors of OHCA.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Out-of-hospital cardiac arrest; Outcome; Prognostic factor; Sinus bradycardia; Target temperature management; Therapeutic hypothermia

Mesh:

Year:  2015        PMID: 25619443     DOI: 10.1016/j.resuscitation.2014.12.031

Source DB:  PubMed          Journal:  Resuscitation        ISSN: 0300-9572            Impact factor:   5.262


  5 in total

1.  What can a simple measure of heart rate during temperature management tell us on the physiology and prognosis of comatose cardiac arrest patients?

Authors:  Jakob Hartvig Thomsen; Christian Hassager; Jesper Kjaergaard
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

2.  European Resuscitation Council and European Society of Intensive Care Medicine guidelines 2021: post-resuscitation care.

Authors:  Jerry P Nolan; Claudio Sandroni; Bernd W Böttiger; Alain Cariou; Tobias Cronberg; Hans Friberg; Cornelia Genbrugge; Kirstie Haywood; Gisela Lilja; Véronique R M Moulaert; Nikolaos Nikolaou; Theresa Mariero Olasveengen; Markus B Skrifvars; Fabio Taccone; Jasmeet Soar
Journal:  Intensive Care Med       Date:  2021-03-25       Impact factor: 17.440

3.  Adverse events associated with poor neurological outcome during targeted temperature management and advanced critical care after out-of-hospital cardiac arrest.

Authors:  Young-Min Kim; Chun Song Youn; Soo Hyun Kim; Byung Kook Lee; In Soo Cho; Gyu Chong Cho; Kyung Woon Jeung; Sang Hoon Oh; Seung Pill Choi; Jong Hwan Shin; Kyoung-Chul Cha; Joo Suk Oh; Hyeon Woo Yim; Kyu Nam Park
Journal:  Crit Care       Date:  2015-07-22       Impact factor: 9.097

Review 4.  Targeted temperature management in neurological intensive care unit.

Authors:  Sombat Muengtaweepongsa; Winchana Srivilaithon
Journal:  World J Methodol       Date:  2017-06-26

Review 5.  Heart rate and diastolic arterial pressure in cardiac arrest patients: A nationwide, multicenter prospective registry.

Authors:  Chul Han; Jae Hoon Lee
Journal:  PLoS One       Date:  2022-09-14       Impact factor: 3.752

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.